Sage Therapeutics Reveals Phase 2 LIGHTWAVE Study Insights
Sage Therapeutics and the LIGHTWAVE Study Findings
Sage Therapeutics, Inc. (Nasdaq: SAGE) recently announced topline results from their critical Phase 2 LIGHTWAVE Study, focusing on dalzanemdor (SAGE-718) as a potential treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s Disease (AD). Conducted over a 12-week period, this randomized, double-blind, placebo-controlled study aimed to assess the efficacy of dalzanemdor in impacting cognitive function in affected participants.
Study Overview and Key Findings
The LIGHTWAVE Study encompassed 174 participants who underwent careful evaluation during the trial. The primary outcome measure utilized was the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test score, assessed at Day 84. Unfortunately, the study did not reveal a statistically significant difference in the cognitive scores for those treated with dalzanemdor compared to the placebo group. This outcome has led Sage Therapeutics to reassess the future trajectory of dalzanemdor's development in Alzheimer's treatment.
Summary of LIGHTWAVE Study Results
The findings from the LIGHTWAVE Study are noteworthy:
- The intervention did not yield statistically significant improvements in the cognitive test scores.
- Dalzanemdor demonstrated a favorable safety profile, with most treatment-emergent adverse events classified as mild to moderate.
- Exploratory analyses also indicated no significant differences between the dalzanemdor treatment group and the placebo group on other cognitive assessments, such as RBANS total score or MoCA total score.
The Next Steps for Dalzanemdor
In light of these findings, Sage Therapeutics has decided not to pursue further clinical development of dalzanemdor for Alzheimer’s Disease. However, the company remains focused on its ongoing Phase 2 DIMENSION Study, evaluating dalzanemdor for cognitive impairment associated with Huntington's Disease. Results from this study are expected to provide further insights into the drug's potential applications.
Insights from Sage Therapeutics' CEO
Barry Greene, CEO of Sage Therapeutics, expressed gratitude towards participants and contributors to the LIGHTWAVE Study, emphasizing the complexities surrounding Alzheimer's Disease. He stated, "While we are disappointed by the results of the LIGHTWAVE Study, we recognize the critical need for more effective treatments for individuals suffering from mild cognitive impairment and mild dementia related to Alzheimer’s. Our commitment is to foster research that informs and guides future studies in this area."
About Dalzanemdor (SAGE-718)
Dalzanemdor is a unique investigational compound classified as an NMDA receptor positive allosteric modulator (PAM). Although its primary focus has been on Alzheimer's, Sage Therapeutics is also exploring its efficacy in other cognitive disorders, including Huntington’s Disease. The commitment to research and development remains a core aspect of Sage's operations as they strive to meet unaddressed needs in brain health.
About Sage Therapeutics
Founded in 2010 and based in Cambridge, Mass., Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company dedicated to advancing innovative treatments that can significantly improve brain health. Sage is recognized for developing two FDA-approved medications for postpartum depression and is actively expanding its pipeline to address unmet medical needs in the domain of mental health and cognitive function. You can learn more about their endeavors on their official website, social media platforms, and other engagement avenues.
Frequently Asked Questions
What is dalzanemdor (SAGE-718)?
Dalzanemdor is an investigational medication designed as an NMDA receptor positive allosteric modulator, primarily studied for cognitive impairment in Alzheimer’s Disease and Huntington’s Disease.
What were the results of the LIGHTWAVE Study?
The LIGHTWAVE Study did not show statistically significant improvements in cognitive test scores among participants treated with dalzanemdor compared to those receiving a placebo.
Is Sage Therapeutics continuing development of dalzanemdor?
Sage Therapeutics has decided not to pursue further clinical development of dalzanemdor for Alzheimer's Disease after the LIGHTWAVE Study results.
What future studies are planned for dalzanemdor?
Sage Therapeutics is focusing on the ongoing Phase 2 DIMENSION Study for cognitive impairment associated with Huntington’s Disease, with results expected later this year.
How is Sage Therapeutics related to Alzheimer's treatment?
Sage Therapeutics is involved in research and development of treatments for brain health, including promising studies aiming to address cognitive impairments related to Alzheimer’s Disease.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Projected Growth of Burn-off Oven Market Through 2034
- Recent Options Activity Reveals Insights on Roblox Stock
- Insights on Top Tech Stocks for Today's Trading Session
- Peripheral Vascular Devices Projected to Surge in Demand by 2029
- How Moms' Votes Will Influence the 2024 Presidential Election
- KITT Stock Sees 52-Week Low Amid Market Uncertainties
- Exxon Mobil's Strategic Floating Rate Notes Issue: Key Insights
- Concentrix Faces 52-Week Low: Insights and Growth Opportunities
- Join Nucor's Upcoming Conference Call for Q3 2024 Insights
- Apex Technology Acquisition Corp. Sees Stock Growth at $12.1
Recent Articles
- U.S. GoldMining Sees Resource Estimate Surge to 10.64 Million AuEq Oz
- Ares Management Unveils New Offering of Convertible Preferred Stock
- Air Lease Corporation's Q3 2024 Aircraft Investments Overview
- U Power Limited Delivers Impressive Financial Growth in H1 2024
- Singulate Secures $2.3 Million Pre-Seed Investment for AI Growth
- Trilogy Metals Posts Third Quarter 2024 Financial Summary
- Dino Ying Steps Down as CEO of VSPO, Danny Tang Takes Lead
- VIAVI Solutions Launches Innovative VALOR Lab for Open RAN Testing
- Transforming Financial Management: CGI Advantage ERP Launch
- Plansight Launches Innovative AI Tool to Enhance Employer Benefits
- Trilogy Metals Delivers Strong Third Quarter Fiscal Results
- HockeyStack Enhances LinkedIn Ads for B2B Revenue Growth
- Enhancing Legal Assistance: Legal-Bay's New Webpage
- U.S. GoldMining Achieves Significant Mineral Resource Growth
- New 9th Circuit Ruling on FBAR Penalties Includes Recklessness
- Federal Reserve's Challenges in Changing Bank Stigma Dynamics
- U.S. Futures Rise as Inflation Data and Earnings Approach
- UK Imposes Sanctions on Russian Military for Chemical Warfare
- Examining the Future of Key Tech Stocks Amid Policy Changes
- Understanding the Current Economic Landscape and Stock Market Dynamics
- Exploring the Future of the Amino Acids Market Growth
- Counterpart Health Welcomes Dr. David Tsay as CMO
- Barings BDC, Inc. Prepares for Upcoming Q3 Results Announcement
- Earnings Season Begins: Key Players in Focus and Expectations
- China's Golden Week Home Sales See Significant Surge
- How Falling Mortgage Rates Transform Real Estate Markets
- PepsiCo's Revenue Decline Triggers Concern Over Sales Outlook
- PepsiCo Reports Earnings: Revenue Decline and Revised Growth Outlook
- U.S. DOJ Proposes Actions for Google to Enhance Search Rivalry
- Honeywell Considers Spinning Off Advanced Materials Division
- Market Fluctuations: Analyzing Global Financial Trends Today
- Positive Trends in China and US Markets Amid Bullish Flows
- MolecuLight's Study Revolutionizes Antimicrobial Practices
- Nexteer Automotive's Stock Surge: JPMorgan's Upgraded Outlook
- MolecuLight's Innovative Study Impacts Wound Care Practices
- Ping An Bank's Stock Upgrade Signals Strong Future Potential
- Celebrating Employee Ownership: A Commitment to Integrity
- JPMorgan Upgrades Huayu Automotive Amid EV Market Growth
- Potential Surge in Bicara Therapeutics Stock Amid Drug Developments
- Vestis Corp: Navigating Challenges in Stock Recovery
- Honeywell Announces Strategic Spin-off for Advanced Materials Unit
- Ares Management's Strategic Move to Enhance Global Reach
- Positive News for CareDx: DOJ Investigation Closed Without Charges
- PepsiCo Delivers Strong Earnings Despite Revenue Challenges
- Tesla's Musk Reveals Ambitious Plans for Robotaxi Industry
- Shifts in Halloween Candy: Chocolates Take a Backseat
- Exploring Economic Trends and Wealth Dynamics in 2024
- Nvidia's Stock Journey: Predictions and Future Growth Potential
- Exploring High-Yield Dividend Stocks Amid Market Turbulence
- Market Reactions to Stimulus and Bitcoin's Latest Moves